CG Oncology Corp (CGON) Total Debt to Capital

CG Oncology, Inc. (CGON) develops methods to combat bladder cancer, focusing on patient medical needs regardless of market cycles. The company is implementing sustainable biomaterial logistics and automating laboratory reports via digital algorithms. The stock price trend on GURU.Markets confirms this data, while the individual debt-to-equity ratio stands at 0.01.

To filter out the issuer's debt risks, it is critical to assess the balance between borrowed funds and equity reserves. By analyzing the financing structure chart (debt-to-equity), an investor can see the proportion of total debt to equity, which determines the degree of financial autonomy of CG Oncology, Inc. (CGON) when upgrading certified facilities and producing drugs for clinical trials.